MARC record from Internet Archive

LEADER: 03870cam 2201021 i 4500
001 ocm06554157
003 OCoLC
005 20220722030836.0
008 800630s1980 gw a b 100 0 eng
010 $a 80018852
040 $aDLC$beng$cDLC$dNLM$dMUQ$dNLGGC$dAU@$dZWZ$dY9F$dUKMGB$dX2#$dBDX$dOCLCQ$dOCLCF$dOCLCO$dOCLCQ$dOCL$dOCLCO$dOCLCQ$dOCLCO$dYDXCP$dOCLCO$dOCLCA$dOCLCO
016 7 $a8005984$2DNLM
016 7 $a012113321$2Uk
019 $a6531482$a636742354
020 $a0387101624$q(U.S. ;$qv. 1)
020 $a9780387101620$q(U.S. ;$qv. 1)
020 $a0387101632$q(U.S. ;$qv. 2)
020 $a9780387101637$q(U.S. ;$qv. 2)
020 $a3540101624
020 $a9783540101628
020 $z0540101632$q(v. 2)
020 $a3540101632
020 $a9783540101635
035 $a(OCoLC)6554157$z(OCoLC)6531482$z(OCoLC)636742354
050 00 $aRC261$b.R35 vol. 74-75$aRC271.C5
060 00 $aW1$bRE106P v.74-75 1980
060 10 $aQZ 267$bC2143 1979
082 00 $a616.99/4 s$a616.99/4061$219
084 $aHE 65$2blsrissc
084 $aGT 90$2blsrissc
084 $aHE 66$2blsrissc
110 2 $aEuropean Organization for Research on Treatment of Cancer.
245 10 $aCancer chemo- and immunopharmacology /$cedited by G. Mathé and F.M. Muggia.
260 $aBerlin ;$aNew York :$bSpringer-Verlag,$c1980.
300 $a2 volumes :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aRecent results in cancer research ;$v74-75
500 $a"Communications presented at the 1979 EORTC annual plenary session on cancer chemo- and immunopharmacology."
504 $aIncludes bibliographical references.
505 0 $aChemopharmacology. -- 2. Immunopharmacology, relations, and general problems.
650 0 $aCancer$xChemotherapy$vCongresses.
650 0 $aAntineoplastic agents$xTesting$vCongresses.
650 0 $aImmunopharmacology$vCongresses.
650 0 $aCancer$xChemotherapy$xCongresses.
650 0 $aCancer$xImmunological aspects$xCongresses.
650 0 $aImmunotherapy$xCongresses.
650 0 $aImmunotherapy.
650 0 $aAntineoplastic agents.
650 0 $aAntimitotic agents.
650 2 $aAntineoplastic Agents
650 2 $aImmunotherapy
650 2 $aNeoplasms$xdrug therapy
650 2 $aAntimitotic Agents
650 6 $aCancer$xChimiothérapie$xCongrès.
650 6 $aAnticancéreux$xEssais$xCongrès.
650 6 $aCancer$xImmunologie$xCongrès.
650 6 $aImmunothérapie$xCongrès.
650 6 $aCancer$xChimiothérapie$vCongrès.
650 6 $aImmunopharmacologie$vCongrès.
650 6 $aAnticancéreux.
650 6 $aImmunothérapie.
650 7 $aAntineoplastic agents$xTesting.$2fast$0(OCoLC)fst00810608
650 7 $aCancer$xChemotherapy.$2fast$0(OCoLC)fst00845327
650 7 $aImmunopharmacology.$2fast$0(OCoLC)fst00968030
650 17 $aKanker.$2gtt
650 17 $aFarmacotherapie.$2gtt
650 17 $aImmunotherapie.$2gtt
650 7 $aImmunopharmacologie$xCongrès.$2ram
650 7 $aAnticancéreux$xTests$xCongrès.$2ram
650 7 $aCancer$xChimiothérapie$xCongrès.$2ram
655 2 $aCongress
655 7 $aConference papers and proceedings.$2fast$0(OCoLC)fst01423772
655 7 $aConference papers and proceedings.$2lcgft
655 7 $aActes de congrès.$2rvmgf
700 1 $aMathé, Georges.
700 1 $aMuggia, Franco M.
830 0 $aRecent results in cancer research ;$v74-75.
938 $aBrodart$bBROD$n32549776$c$66.00
938 $aYBP Library Services$bYANK$n12297200
029 1 $aAU@$b000001758276
029 1 $aHEBIS$b048840777
029 1 $aNLM$b8005984
029 1 $aNZ1$b4310859
029 1 $aUKMGB$b012113321
994 $aZ0$bIME
948 $hNO HOLDINGS IN IME - 144 OTHER HOLDINGS